Ultrasound-guided percutaneous ablation treatment for current hepatoblastoma: initial single-center experience
10.3760/cma.j.issn.1008-1372.2017.06.005
- VernacularTitle:超声引导下经皮消融治疗复发性肝母细胞瘤的初步研究
- Author:
Pengliang LI
;
Jia LUO
;
Xiaoer ZHANG
;
Baoxian LIU
;
Luyao ZHOU
;
Guangliang HUANG
;
Quanyuan SHAN
;
Xiaoyan XIE
- Keywords:
Ultrasonography;
Catheter ablation;
Liver neoplasms/SU;
Recurrence
- From:
Journal of Chinese Physician
2017;19(6):813-816
- CountryChina
- Language:Chinese
-
Abstract:
Objective To summarize the first experience with ultrasound-guided percutaneous ab lation treatment (PAT) for recurrent hepatoblastoma (HB) after liver resection in children.Methods From August 2013 to April 2015,PAT was used to treat 6 children with a total of 9 recurrent HB,including 5 patients with 8 tumors in the liver and 1 patient with 1 tumor in the lung.The mean size of ablated tumors was (1.5 ± 0.8) cm,and the tumor size range was 0.7 cm to 3.1 cm.Results Four patients were performed percutaneous radiofrequency ablation (RFA) for recurrent HB;and 2 patients were performed percutaneous ethanol injection (PEI).Ablation success was achieved in all patients (6/6,100％).The complete ablation rate after the first ablation session was 88.9％ (8/9) on a tumor-by-tumor basis.Only 1 patient developed a fever with temperature ＞ 39 ℃;it was resolved by conservative therapy.During the follow-up period of 5-30 months,3 patients died to tumor progression.The 1-and 2-year overall survival rates after ablation were 83.3％ and 41.7％,respectively.Conclusions PAT is a safe and promising therapy for children with recurrent HB after liver resection,and further investigation in large-scale randomized clinical trials is required to determine its role in the treatment of this disease.
